Researchers found that the combination of benmelstobart, chemotherapy, and anlotinib yields improved response and progression-free survival in patients with advanced or recurrent endometrial cancer,...
The results of a large retrospective analysis noted significant age-related differences in the germline landscape of endometrial cancer. This study was presented as a poster at the 2025 American Society of...
A phase 2 study evaluating the safety and efficacy of letrozole, abemaciclib, and metformin in treating estrogen receptor–positive recurrent endometrial cancer highlights promising outcomes in a select...
A post hoc analysis of the DUO-E trial evaluated how durvalumab and maintenance olaparib influenced circulating tumor DNA dynamics in first-line endometrial cancer treatment.
A retrospective analysis presented at the American Society of Clinical Oncology 2025 Annual Meeting suggests that higher tumor mutational burden (TMB) may be linked to longer progression-free survival in...
The 2025 American Society of Clinical Oncology guideline update redefines the role of sentinel lymph node biopsy (SLNB) in early-stage breast cancer. Building on evidence from major trials, the update...
The latest OVATION-2 trial update, presented at the American Society of Clinical Oncology 2025 annual meeting, shows that adding intraperitoneal IMNN-001 to standard neoadjuvant chemotherapy improved both...
A phase II trial evaluating pembrolizumab plus lenvatinib in clear cell ovarian carcinoma shows promising response rates and 6-month progression-free survival.
A retrospective analysis from Memorial Sloan Kettering links higher patient-reported pain to increased emergency department utilization among individuals newly diagnosed with ovarian cancer. This study was...
Patients with endometriosis face significantly higher risks of postoperative complications when undergoing surgery for stage I endometrial cancer, according to a new study presented at the Society of...
